The 49-page complaint was filed October 1 in St. Lucie County, Florida, naming Pfizer and its CEO as defendants under the state’s Deceptive and Unfair Trade Practices Act.
The complaint begins with a statement from 2021 that has resurfaced, aimed clearly at the Pfizer CEO: “Those people are criminals.”
That remark highlights Bourla’s portrayal of individuals expressing safety concerns about Pfizer’s COVID-19 shot.
In a conversation with Atlantic Council CEO Frederick Kempe, Bourla stated, “Those people are criminals. They’re not bad people. They’re criminals because they have literally cost millions of lives.”
As noted by the Florida attorney general in his X post, Dr. Anthony Fauci and the biomedical community were aware of the risks associated with the COVID shots but opted to keep this information hidden from the public.
Pfizer now faces the lawsuit for allegedly misleadingly the public by promoting their products as safe in a similar manner.
While the pharmaceutical giant publicly guaranteed the safety of its vaccine to the American public, it was allegedly in possession of both internal and external safety data concerning myocarditis, pericarditis, miscarriages, strokes, other adverse events, and even fatalities.
“This Adverse Event Data was collected by Pfizer but was not released to the public,” states the complaint. “It only came to light much later, when it was disclosed pursuant to a court order in hard-fought FOIA litigation.”
As of February 28, 2021, just ten weeks following the emergency use authorization granted to Pfizer, the complaint reveals that the pharmaceutical company reported a staggering total of 158,893 adverse events (from 42,086 case reports) linked to its COVID-19 shot.
In what appears to be a blatant lie, from January 2023, Bourla claimed that Pfizer had observed “not a single [safety] signal,” despite the administration of billions of doses.
It was also disclosed in today’s filing that Pfizer’s database showed a total of 1,223 fatalities following the administration of its COVID-19 shot. However, the pharmaceutical company “did not make causality findings.”
The complaint further indicates that Pfizer received reports concerning 458 pregnant women who were exposed to its COVID vaccine. Among these reports, 248 indicated adverse events, while 52 were related to miscarriages. Notably, almost all of the reported miscarriages took place during the first trimester.
It also highlights that Pfizer has openly acknowledged COVID-19 shot was not tested for its effectiveness in preventing virus transmission.
In response to the question, “Was the Pfizer COVID vaccine tested on stopping the transmission of the virus before it entered the market?” Janine Small, Pfizer’s director of International Developed Markets, confirmed, “No.”
Furthermore, the complaint alleges that Pfizer transformed around $1.5 billion in research and development expenditures into over $80 billion in revenue from its COVID vaccine. According to the figures mentioned in the complaint, Pfizer’s vaccine dominated nearly 70 percent of the COVID vaccine markets in both the U.S. and Europe. Additionally, Bourla reportedly earned approximately $101.8 million in compensation from the company between 2020 and 2023.
Florida is demanding restitution as the attorney general moves to request civil penalties from Pfizer. The court filing seeks a permanent injunction against any deceptive or unfair representations regarding the company’s COVID shot, along with attorneys’ fees and additional relief.
The AG is also pursuing disgorgement, a legal term indicating that Pfizer could be compelled to return profits linked to actions that the court may find in violation of state law.
As the lawsuit unfolds, the implications for Pfizer and its leadership could be significant, potentially reshaping the landscape of pharmaceutical accountability and public trust.
Florida’s attorney general’s legal action also highlights the ongoing concerns surrounding mRNA shot safety and transparency.
The outcome of this case could resonate far beyond Florida, influencing future regulations and the expectations placed on pharmaceutical companies regarding the disclosure of critical safety data.
